Results 11 to 20 of about 857,892 (246)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

New England Journal of Medicine, 2021
Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting.
N. Dagan, N. Barda, Eldad Kepten, O. Miron, Shay Perchik, M. Katz, M. Hernán, M. Lipsitch, B. Reis, R. Balicer   +9 more
semanticscholar   +1 more source

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

New England Journal of Medicine, 2022
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly vaccinated populations has aroused concerns about the effectiveness of current ...
N. Andrews, J. Stowe, Freja C M Kirsebom, S. Toffa, T. Rickeard, E. Gallagher, C. Gower, M. Kall, N. Groves, A. O’Connell, D. Simons, P. Blomquist, A. Zaidi, S. Nash, Nurin Iwani Binti Abdul Aziz, S. Thelwall, G. Dabrera, R. Myers, G. Amirthalingam, S. Gharbia, J. Barrett, R. Elson, S. Ladhani, N. Ferguson, M. Zambon, C. Campbell, K. Brown, S. Hopkins, M. Chand, M. Ramsay, J. Lopez Bernal   +30 more
semanticscholar   +1 more source

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

New England Journal of Medicine, 2021
Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.
J. Sadoff, G. Gray, A. Vandebosch, V. Cárdenas, Georgi Shukarev, B. Grinsztejn, P. Goepfert, C. Truyers, H. Fennema, B. Spiessens, K. Offergeld, Gert Scheper, K. Taylor, M. Robb, J. Treanor, D. Barouch, J. Stoddard, M. Ryser, M. Marovich, K. Neuzil, L. Corey, N. Cauwenberghs, T. Tanner, K. Hardt, Javier Ruiz-Guiñazú, Mathieu le Gars, H. Schuitemaker, J. van Hoof, F. Struyf, M. Douoguih   +29 more
semanticscholar   +1 more source

COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates

Vaccines, 2021
Utility of vaccine campaigns to control coronavirus 2019 disease (COVID-19) is not merely dependent on vaccine efficacy and safety. Vaccine acceptance among the general public and healthcare workers appears to have a decisive role in the successful ...
Malik Sallam
semanticscholar   +1 more source

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic.
F. Polack, Stephen J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, E. Moreira, C. Zerbini, R. Bailey, K. Swanson, Satrajit Roychoudhury, K. Koury, Ping Li, W. Kalina, David Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber   +28 more
semanticscholar   +1 more source

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.

New England Journal of Medicine, 2023
BACKGROUND Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain.
B. Kampmann, S. Madhi, I. Munjal, E. Simões, B. Pahud, C. Llapur, J. Baker, Gonzalo Pérez Marc, D. Radley, Emma Shittu, Julia R Glanternik, Hasra K Snaggs, James Baber, Philip Zachariah, S. Barnabas, Merlin Fausett, Tyler Adam, Nicole Perreras, M. V. van Houten, A. Kantele, Li-Min Huang, L. Bont, Takeo Otsuki, Sergio L Vargas, Joanna Gullam, B. Tapiéro, R. Stein, F. Polack, H. Zar, N. B. Staerke, María Duron Padilla, Peter C. Richmond, K. Koury, Katherine Schneider, E. V. Kalinina, David Cooper, K. Jansen, A. Anderson, K. Swanson, W. Gruber, A. Gurtman   +40 more
semanticscholar   +1 more source

Psoriasis: To Vaccinate or Not to Vaccinate? [PDF]

Cureus, 2021
Psoriasis is a chronic, inflammatory, autoimmune disease characterized by red, dry, itchy, and scaly patches of abnormal skin growth on the elbows, knees, and/or scalp, which can negatively impact a patient's quality of life and activities of daily living.
Marc M Kesselman, Michelle Demory Beckler, Poonam Patel, Christian Summa   +3 more
openaire   +3 more sources

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

New England Journal of Medicine, 2020
Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine that encodes the prefusion ...
L. Baden, Hana M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. Spector, N. Rouphael, C. Creech, J. Mcgettigan, Shishir Kehtan, N. Segall, Joel Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, Honghong Zhou, Shu Han, M. Ivarsson, Jacqueline M. Miller, T. Zaks   +36 more
semanticscholar   +1 more source

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

New England Journal of Medicine, 2023
BACKGROUND Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection, lower respiratory tract disease, clinical complications, and death in older adults.
A. Papi, M. Ison, J. Langley, Dong-Gun Lee, I. Leroux-Roels, F. Martinón-Torres, T. Schwarz, R. V. van Zyl-Smit, L. Cámpora, N. Dezutter, N. De Schrevel, L. Fissette, M. David, M. van der Wielen, L. Kostanyan, Veronica Hulstrøm   +15 more
semanticscholar   +1 more source

A global survey of potential acceptance of a COVID-19 vaccine

Nature Network Boston, 2020
Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine.
J. Lazarus, S. Ratzan, Adam Palayew, L. Gostin, H. Larson, Kenneth H. Rabin, S. Kimball, A. El-Mohandes   +7 more
semanticscholar   +1 more source